Home > Boards > US Listed > Medical - Equipment > BrainsWay (BWAY)

Analysts Estimate Report : What to Look Out

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 125
Posts 25,552
Boards Moderated 9
Alias Born 02/07/04
160x600 placeholder
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 6/17/2021 5:00:55 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/3/2021 9:31:09 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 6/3/2021 9:29:07 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/2/2021 8:00:58 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/1/2021 8:01:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/24/2021 8:01:03 AM
Brainsway EPS misses by $0.03, beats on revenue Seeking Alpha - 5/20/2021 8:09:26 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/20/2021 8:01:04 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/5/2021 8:00:57 AM
Tender Offer Statement by Issuer (sc To-i) Edgar (US Regulatory) - 5/4/2021 9:29:32 AM
BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month GlobeNewswire Inc. - 5/4/2021 9:02:00 AM
BrainsWay launches noninvasive treatment for smoking addiction Seeking Alpha - 4/29/2021 9:10:50 AM
BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers GlobeNewswire Inc. - 4/29/2021 9:03:00 AM
RIOT, MARA, OCGN and MVIS among notable premarket gainers Seeking Alpha - 4/26/2021 8:21:35 AM
BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment Seeking Alpha - 4/26/2021 7:43:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/26/2021 7:30:54 AM
BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder GlobeNewswire Inc. - 4/26/2021 7:30:00 AM
BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS) GlobeNewswire Inc. - 4/14/2021 9:03:00 AM
Brainsway EPS beats by $0.03, beats on revenue Seeking Alpha - 3/24/2021 4:24:50 PM
BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full E... GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares GlobeNewswire Inc. - 2/23/2021 8:30:00 AM
BrainsWay readies ADS offering Seeking Alpha - 2/22/2021 4:06:39 PM
BrainsWay Ltd. Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 2/22/2021 4:02:00 PM
BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales GlobeNewswire Inc. - 2/16/2021 7:30:00 AM
BrainsWay Reports Preliminary Record Fourth Quarter Revenue and Full-Year 2020 Financial Results GlobeNewswire Inc. - 2/16/2021 7:00:00 AM
midastouch017   Thursday, 06/11/20 02:46:37 AM
Re: None
Post # of 29 
Analysts Estimate Report : What to Look Out for BRAINSWAY LTD/S ADR (NASDAQ:BWAY)

By Ronald -June 10, 2020017

Earnings results for BRAINSWAY LTD/S ADR (NASDAQ:BWAY)
Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingMar 2020 , the consensus EPS* forecast has remained the same over the past week at -0.16 and remained the same over the past month at -0.16. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -0.48 and remained the same over the past month at -0.48 . none raised and none lowered their forecast.

BRAINSWAY LTD/S last announced its quarterly earnings results on March 23rd, 2020. The reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The business earned $6.29 million during the quarter, compared to analysts’ expectations of $6.25 million. BRAINSWAY LTD/S has generated ($0.50) earnings per share over the last year. BRAINSWAY LTD/S has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, June 10th, 2020 based off prior year’s report dates.

Analyst Opinion on BRAINSWAY LTD/S ADR (NASDAQ:BWAY)
2 Wall Street analysts have issued ratings and price targets for BRAINSWAY LTD/S in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible upside of 56.70%. The high price target for BWAY is $13.00 and the low price target for BWAY is $9.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

BRAINSWAY LTD/S has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $11.00, BRAINSWAY LTD/S has a potential upside of 56.7% from its current price of $7.02. BRAINSWAY LTD/S has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: BRAINSWAY LTD/S ADR (NASDAQ:BWAY)
BRAINSWAY LTD/S does not currently pay a dividend. BRAINSWAY LTD/S does not have a long track record of dividend growth.

Insiders buying/selling: BRAINSWAY LTD/S ADR (NASDAQ:BWAY)
In the past three months, BRAINSWAY LTD/S insiders have not sold or bought any company stock. Only 17.37% of the stock of BRAINSWAY LTD/S is held by institutions.

Earnings and Valuation of BRAINSWAY LTD/S ADR (NASDAQ:BWAY
Earnings for BRAINSWAY LTD/S are expected to grow in the coming year, from ($0.48) to ($0.26) per share. The P/E ratio of BRAINSWAY LTD/S is -14.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of BRAINSWAY LTD/S is -14.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. BRAINSWAY LTD/S has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

https://stockmarketdaily.co/2020/06/10/brainsway-ltd-s-adr-analysts-estimate-report-what-to-look-out-for/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences